QL Biopharm
PrivateLast Round
Series C
Mar 2, 2026
Est. Valuation
$417.5M
Total Funding Raised
$158.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
QL Biopharm operates in Healthcare & Life Sciences and is based in Beijing. Its latest recorded funding round was a Series C round in March 2026.
QL Biopharm is a biotechnology company that develops innovative drugs for chronic metabolic diseases such as obesity, diabetes, and non-alcoholic fatty liver disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
QL Biopharm Comparables
Compare QL Biopharm with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sciwind Biosciences | 85% | |
| PegBio Co Ltd | 81% | |
| Gmax Biopharm | 80% |
For institutional investors. Book with your work email.
QL Biopharm Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Mar 2, 2026 | ||||
| Series C | Feb 17, 2025 | ||||
| Series B Extension | Nov 27, 2023 | ||||
| Series B | Mar 6, 2023 | ||||
| Series B | Feb 15, 2022 | ||||
Series A | Oct 27, 2020 |
For institutional investors. Book with your work email.
QL Biopharm Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Lanchi Ventures | Series B Extension, Series B |
| BioTrack Capital | Series A |
| TF Capital | Series C |
| Jiyuan Capital | Series B Extension |
| Tigeryeah Capital | Series C, Series A |
| OrbiMed | Series C |
| 中国风险投资有限公司 | Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 2, 2026
$72M round led by OrbiMed
- Nov 27, 2023
$28M round led by China-US Green Fund and Imeik Technology.
For institutional investors. Book with your work email.
QL Biopharm Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about QL Biopharm's valuation, stock price, and market status.
Is QL Biopharm a public or private company?
QL Biopharm is a private company.
What is the current stock price of QL Biopharm?
QL Biopharm is a private company, so its shares have no public market price. Caplight tracks QL Biopharm's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is QL Biopharm worth (valuation)?
QL Biopharm's valuation is estimated at $417.5M based on funding round data.
Can I buy QL Biopharm stock?
QL Biopharm shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was QL Biopharm's last funding round?
QL Biopharm's most recent funding round was Series C on March 2, 2026.
Who are the main investors in QL Biopharm?
Key investors in QL Biopharm include Lanchi Ventures, OrbiMed, 中国风险投资有限公司, BlueRun Ventures, China-US Green Fund.
Will QL Biopharm IPO soon?
No public IPO plans have been announced for QL Biopharm.
How can I track QL Biopharm secondary market activity?
Caplight tracks bids, offers, and trades in QL Biopharm's shares on secondary markets.